IHS Chemical Week

People & Business :: Companies

DSM Biologics and Crucell Enter Licensing Deal

2:08 PM MDT | August 20, 2007 | Michelle Bryner

DSM Biologics and Crucell (Leiden, the Netherlands) have entered into an agreement to license a new manufacturing technology based on the companies’ jointly developed PER.C6 cell line, to LFB Biotechnologies (Paris). Financial details were not disclosed. LFB will use the licensed technology to develop undisclosed antibodies. The companies will also evaluate the potential for a joint collaboration to develop sugar structures on recombinant antibodies using LFB’s proprietary technology. PER.C6 is a human cell line for producing therapeutic recombinant...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.



Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.

 














 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa